<DOC>
	<DOC>NCT02200146</DOC>
	<brief_summary>The aim of the study is determining the non-inferiority in the overall success rate and the safety for a combination therapy with hydroxychloroquine plus low dose glucocorticoids compared to that for high dose glucocorticoids at 3 and 9 months in patients with pulmonary sarcoidosis.</brief_summary>
	<brief_title>Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).</brief_title>
	<detailed_description />
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis, Pulmonary</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>patients between 18 and 70 years parenchymal pulmonary involvement at Chest XRay (CXR) AND one of the follows: physiologic abnormalities on pulmonary function testing and/or respiratory symptoms, and/or exerciseinduced abnormalities. Unable to understand protocol and to sign informed consent or not suitable candidate to comply with the requirements of this study, in the opinion of the investigator Cardiac and neurological sarcoidosis or any other organ involvement End stage lung disease at highresolution computed tomography (HRCT) Clinical evidence of active infection Documented exposure to beryllium Patients with Forced Expiratory Volume at one second (FEV1) changes after salbutamol inhalation â‰¥20% Comorbidity: advanced liver cirrhosis or abnormal liver function, unstable cardiac disease, moderate to severe renal insufficiency, poorly controlled diabetes Pregnancy or lactation A tuberculin skin test (5 I.U.) more than 5 mm Psoriasis Homozygous glucose6phosphatase deficiency Known hypersensitivity to hydroxychloroquine or 4aminoquinoline derivatives Visual field changes attributable to 4aminoquinolines Concomitant therapies: any patient enrolled in the study must be off all prohibited medications at least 4 weeks before screening. Once patients completed the washout period, they may enter the screening period that may last up to 30 days Previous therapies: any patient enrolled must be off all medications for sarcoidosis at least 4 weeks before screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>sarcoidosis</keyword>
	<keyword>treatment</keyword>
	<keyword>lung</keyword>
	<keyword>glucocorticoids</keyword>
	<keyword>hydroxychloroquine</keyword>
</DOC>